Abstract
Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.
| Original language | English |
|---|---|
| Pages (from-to) | 96-101 |
| Number of pages | 6 |
| Journal | International Journal of Cardiology |
| Volume | 132 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2009 Feb 6 |
Fingerprint
Keywords
- Arterial stiffness
- Cardiovascular disease
- esRAGE
- Inflammation
- Type 2 diabetes
ASJC Scopus subject areas
- Medicine(all)
- Cardiology and Cardiovascular Medicine
Cite this
Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. / Choi, Kyung Mook; Yoo, Hye-Jin; Kim, H. Y.; Lee, K. W.; Seo, Ji A; Kim, Sin Gon; Kim, Nan Hee; Choi, D. S.; Baik, Sei-Hyun.
In: International Journal of Cardiology, Vol. 132, No. 1, 06.02.2009, p. 96-101.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness
AU - Choi, Kyung Mook
AU - Yoo, Hye-Jin
AU - Kim, H. Y.
AU - Lee, K. W.
AU - Seo, Ji A
AU - Kim, Sin Gon
AU - Kim, Nan Hee
AU - Choi, D. S.
AU - Baik, Sei-Hyun
PY - 2009/2/6
Y1 - 2009/2/6
N2 - Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.
AB - Background: Advanced glycation end products (AGEs) and its receptor (RAGE) were known to play a pivotal role in the development of cardiovascular complications of diabetes. We investigated the association between circulating endogenous secretory RAGE (esRAGE) levels, inflammatory markers and arterial stiffness measured using brachial-ankle pulse wave velocity (baPWV). Methods: The study subjects were composed of 76 type 2 diabetic patients and 78 age- and sex-matched non-diabetic subjects. Results: Circulating esRAGE levels were significantly lower in subjects with type 2 diabetes (0.237 ± 0.123 ng/ml vs. 0.307 ± 0.177 ng/ml, p = 0.005), and those levels were inversely correlated with body mass index (BMI), waist circumference, blood pressure, triglyceride, fasting glucose level and insulin resistance. Furthermore, esRAGE levels were significantly associated with adiponectin (r = 0.164, p = 0.044), interleukin-6 (IL-6) (r = - 0.242, p = 0.009) levels and baPWV (r = - 0.296, p < 0.001). Multiple regression analysis showed that fasting insulin, IL-6, glucose level and insulin resistance are major factor determining esRAGE (R2 = 0.186). Moreover, baPWV was found to be associated with age, systolic blood pressure, triglyceride, sex, BMI, fasting insulin and esRAGE level (R2 = 0.583). Conclusions: Circulating esRAGE levels were significantly lower in type 2 diabetic patients, and were associated with inflammation and arterial stiffness. These results suggest that esRAGE may play an important role on ligand-RAGE interaction propagated inflammation and atherosclerosis.
KW - Arterial stiffness
KW - Cardiovascular disease
KW - esRAGE
KW - Inflammation
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=58849111810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58849111810&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2007.10.047
DO - 10.1016/j.ijcard.2007.10.047
M3 - Article
VL - 132
SP - 96
EP - 101
JO - International Journal of Cardiology
JF - International Journal of Cardiology
SN - 0167-5273
IS - 1
ER -